Drs. Louise de Swart

Louise de Swart

Iron toxicity in lower risk MDS.  Specific interest includes direct and long term iron toxicity in these patients due to supportive care with red blood cell transfusions or intrinsic

back to our team


Publications by Louise de Swart

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes de Swart, Reiniers, Bagguley, van Marrewijk, Bowen, Hellström-Lindberg, Tatic, Symeonidis, Huls, Cermak, van de Loosdrecht, Garelius, Culligan, Macheta, Spanoudakis, Panagiotidis, Krejci, Blijlevens, Langemeijer, Droste, Swinkels, Smith, de Witte, EUMDS
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders de Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MC, Porter JB, Mattijssen VE, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW. Haematologica 2016;101(1):38-45.
Non-transferrin-bound iron: a promising biomarker in iron overload disorders Maas RP, Voets PJ, de Swart L, Swinkels DW. Ned Tijdschr Geneeskd 2013;157(49):A6258.

More publications